Lanean...
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
BACKGROUND: Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options. METHODS: In this open-label, international, phase 3 trial, we randomly assigned 542 patients with advanced urothelial cancer that recurred or...
Gorde:
| Argitaratua izan da: | N Engl J Med |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5635424/ https://ncbi.nlm.nih.gov/pubmed/28212060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1613683 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|